Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.

Authors

Janneke M Brussee
Nienke J Vet
Elke H J Krekels
Abraham J Valkenburg
Evelyne Jacqz-Aigrain
Joop M A van Gerven
Eleonora L Swart
Johannes N van den Anker, George Washington UniversityFollow
Dick Tibboel
Matthijs de Hoog
Saskia N de Wildt
Catherijne A J Knibbe

Document Type

Journal Article

Study Type

Systematic Review

Publication Date

2-2018

Journal

British Journal of Clinical Pharmacology

Volume

84

Issue

2

Inclusive Pages

358-368

DOI

10.1111/bcp.13459

Comments

Reproduced with permission of John Wiley & Sons. British Journal of Clinical Pharmacology

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

APA Citation

Brussee, J., Vet, N., Krekels, E., Valkenburg, A., Jacqz-Aigrain, E., van Gerven, J., Swart, E., van den Anker, J., Tibboel, D., de Hoog, M., de Wildt, S., & Knibbe, C. (2018). Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.. British Journal of Clinical Pharmacology, 84 (2). http://dx.doi.org/10.1111/bcp.13459

Peer Reviewed

1

Open Access

1